Quanterix (QTRX) Canaccord Genuity's 46th Annual Growth Conference summary

Key business drivers and operational updates

• Achieved $85 million in revenue synergies from the Akoya acquisition, completed ERP integration, and disciplined spending to meet synergy targets.

• Clinical trials bookings increased quarter-over-quarter, with dedicated resources now focused on clinical trials to drive larger deals.

• Commercial organization restructured to segment sales by expertise, aiming for deeper customer engagement and sequential growth.

• Added new leadership in commercial and diagnostics, including a Chief Commercial Officer and a diagnostics leader with extensive industry experience.

• Investments in assay development, manufacturing, and marketing expected to drive sequential revenue improvement, especially in Q4.

Market dynamics and competitive positioning

• Biopharma deals remain steady in volume but are smaller in size due to funding constraints; dedicated clinical trials team expected to improve performance.

• Competitors benefited from fewer distractions during company transformation, but renewed focus and specialized teams are expected to regain momentum.

• Platform differentiation centers on ultra-sensitive, reproducible assays critical for clinical trials, especially in neurology.

• Five-marker test offers a lower indeterminate zone and more quantitative results compared to competitors, enhancing appeal for primary care and neurology.

• Partnerships with Tempus AI and reference labs like ARUP are being leveraged to expand reach without building a large sales force.

Diagnostics strategy and growth outlook

• LucentAD Complete is the flagship diagnostic test, with a 510(k) filing in progress and FDA approval anticipated in Q4 or early next year.

• Anthem Blue Cross and Blue Shield began covering blood-based biomarkers, including LucentAD Complete, with a CMS price crosswalk of $897.

• Clinical utility studies underway, with results expected in the second half to support payer discussions and reimbursement expansion.

• Plans to file for 510(k) approval of the HD-X IVD instrument in 2027, enabling both centralized and decentralized diagnostic strategies.

• Diagnostics revenue on track for $10 million in 2026, with infrastructure and billing capabilities being built to support scaling.